|Bid||64.00 x 203800|
|Ask||66.00 x 10000|
|Day's range||60.51 - 61.62|
|52-week range||54.84 - 79.05|
|PE ratio (TTM)||22.33|
|Earnings date||27 Jul 2017|
|Dividend & yield||0.00 (0.00%)|
|1y target est||68.07|
Its partner and its rival have a lot riding on the fate of Evenity.
A bone density drug being co-developed by Amgen, the US biotech, and UCB, the Belgian drugmaker, increased a patient's chances of suffering serious heart problems during a late-stage trial, prompting fears ...
Live coverage of European markets now available on cpurl://apps.cp./cms/?pageId=livemarkets Summary: ** Athens stocks up as euro zone finance ministers meet for Greek deal ** Clariant-Huntsman tie-up takes ...